Mo1023 15 Days of Treatment With Rifaximin Improves Cerebral Blood Flow At Transcranial Doppler and Psychometric Tests in Cirrhotic Patients With Minimal Hepatic Encephalopathy

2014 ◽  
Vol 146 (5) ◽  
pp. S-988
Author(s):  
Gianluigi Caracciolo ◽  
Maria Assunta Zocco ◽  
Brigida E. Annicchiarico ◽  
Andrea Lupascu ◽  
Matteo Garcovich ◽  
...  
1992 ◽  
Vol 12 (1) ◽  
pp. 177-177

Cerebral Ammonia Metabolism in Patients with Severe Liver Disease and Minimal Hepatic Encephalopathy Alan H. Lockwood, Eddy W. H. Yap, and Wai-Hoi Wong [Originally published in Journal of Cerebral Blood Flow and Metabolism 1991;11;337–341] [Originally published in Journal of Cerebral Blood Flow and Metabolism 1991;11;337–341] The first sentence of the third paragraph of the Discussion, on page 339, should read as follows: “In aqueous solutions at physiological pH values, about 1–2% of all ammonia exists as a diffusible gas, with the remainder present as the less mobile charged ammoniumion.”


2013 ◽  
Vol 33 (10) ◽  
pp. 1478-1489 ◽  
Author(s):  
Vicente Felipo ◽  
Amparo Urios ◽  
Pedro Valero ◽  
Mar Sánchez ◽  
Miguel A. Serra ◽  
...  

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Francesca Romana Ponziani ◽  
Barbara Funaro ◽  
Andrea Lupascu ◽  
Maria Elena Ainora ◽  
Matteo Garcovich ◽  
...  

Abstract Minimal hepatic encephalopathy (MHE) is a subclinical complication of liver cirrhosis with a relevant social impact. Thus, there is urgent need to implement easy to use diagnostic tools for the early identification of affected patients. The aim of this study was to investigate cerebral blood flow, systemic hemodynamics as well as endothelial function of cirrhotic patients with MHE, and to verify their change after treatment with rifaximin. Fifty cirrhotic patients with or without MHE and an equal number of healthy controls underwent transcranial Doppler ultrasound (TCD), abdominal Doppler ultrasound (US), and measurement of flow mediated dilation (FMD). In cirrhotic patients diagnosed with MHE receiving rifaximin, the tests were repeated at the end of treatment. Middle (MCA) and posterior (PCA) cerebral artery resistive (RI) and pulsatility (PI) indices were higher in cirrhotic patients than controls, as well as renal and splenic artery RI. Conversely, FMD was reduced. MCA-RI and PI were even higher in cirrhotic patients with MHE compared to those without; a MCA-RI cut-off of 0.65 showed an accuracy of 74% in discriminating the presence of MHE, with 65% sensitivity and 76% specificity. Rifaximin treatment showed no efficacy in the modulation of cerebral vascular flow. In conclusion, cirrhotic patients with MHE have significantly increased cerebral vascular resistances that are not improved by rifaximin treatment. MCA-RI measurement has a good accuracy for the diagnosis of MHE and can be useful for the early identification of this harmful complication of liver cirrhosis.


Hepatology ◽  
1989 ◽  
Vol 9 (3) ◽  
pp. 439-442 ◽  
Author(s):  
Paul Calès ◽  
Max Pierre-Nicolas ◽  
Antonio Guell ◽  
Jean-Louis Mauroux ◽  
Anne Franco-Sempe ◽  
...  

2018 ◽  
Vol 12 (1) ◽  
pp. 15-21
Author(s):  
Shireen Ahmed ◽  
Md Golam Azam ◽  
Indrajit Kumar Datta ◽  
Md Nazmul Hoque ◽  
Tareq M Bhuiyan

Background and objectives: Minimal hepatic encephalopathy (MHE) impairs health related quality of life and predicts overt hepatic encephalopathy (HE) in cirrhotic patients. Lactulose is effective in the treatment of MHE. But the response to lactulose treatment depends on several factors. This study was aimed to find out the contributing factors to non-response to lactulose therapy.Materials and methods: The study was carried out at the BIRDEM general hospital from September, 2013 to March, 2015. Sixty patients were enrolled to assess the response of lactulose therapy in cirrhotic patients with MHE. MHE was diagnosed based on abnormal psychometric tests namely, number connection test (NCT), digit symbol test (DST) and high serum ammonia level. A daily dose of 30-60 ml of lactulose was given to all patients for one month. The response to treatment with regard to MHE was determined after one month using defined criteria. The response was graded as responder and non-responder.Results: The mean age of the study population was 57.0±10.3 years. Out of 60 cases, 46 (77%) were male and 39 (65%) had diabetes. Out of 60 enrolled MHE cases, 16 (27%) had Child-Turcotte-Pugh-A (CTP-A) score and 44 (73%) belonged to CTP-B & C category. Out of 60 MHE cases, 23 (38.3%) showed improvement in their MHE status based on normalization of psychometric tests and reduction of serum ammonia level to ≤32 μmol/L. Age, gender and diabetes were not associated with the response to lactulose therapy. Low baseline arterial pressure was significantly (p=0.003) associated with non-response to lactulose treatment. The mean baseline ammonia level was higher significantly among the nonresponders compared to the responders (83.6±21.4 μmol/L vs 58.8±19.8 μmol/L, p<0.001). Compared to responders, low serum sodium and potassium and raised serum bilirubin levels of non-responders at baseline were found significantly (p<0.05) associated with non-response to one month of lactulose treatment. Initial hemoglobulin, peripheral leucocyte and platelet counts did not have any effect on the response to lactulose treatment in MHE cases.Conclusions: The status of MHE in patients with cirrhosis improved by one-month treatment with lactulose. Baseline low arterial pressure, hyperammonemia, hypokalemia and hyponatremia were major contributors to non-response to lactulose therapy. The findings of the study would be useful in treating patients of cirrhosis with MHE.IMC J Med Sci 2018; 12(1): 15-21


2010 ◽  
Author(s):  
Ελένη Μόκα

BackgroundCerebral haemodynamic and metabolic derangement is well known and common in patients withchronic liver disease or / and cirrhosis. It is often manifested as hepatic encephalopathy, although itscause and pathogenesis are not clearly understood and poorly elucidated. Patients with cirrhosisusually show alterations of cerebral perfusion and oxygenation, as well as changes of systemichaemodynamics and are thus prone to develop arterial hypotension, which might result in brainhypoperfusion, if cerebral autoregulation is impaired. Transcranial Doppler and Cerebral Oximetryare non invasive methods of neurological monitoring and are broadly used in the evaluation of theintracranial circulation and cerebral oxygenation status.Study Aims and ObjectivesThe aim of this open, comparative, non randomized, cross – sectional and longitudinal,observational clinical study was to evaluate brain haemodynamics in patients with chronic liverdisease and to test the degree of impairment of their cerebral autoregulatory mechanism, by usingTranscranial Doppler Ultrasonography. In addition, one of our basic scopes was to compare theseresults with those from Cerebral Oximetry and correlate them with the levels of blood S100bprotein.Material and MethodsOur study consisted of 40 healthy volunteers (Group I) and 40 patients with chronic liver disease(Group II). From those with chronic hepatic disease, 33 had liver cirrhosis (Group IIa) and 7 justchronic liver disease without cirrhosis (Group IIb). Regarding cerebral haemodynamics the baselineparametres that were examined included cerebral blood flow velocities, Vsyst, Vdias, Vmean,Pulsatility and Resistive Indices (PI &RI), as well as rSO2 values from Cerebral Oximetry. All thesevalues were recorded and studied bilaterally. The evaluation of the cerebral autoregulatorymechanism was performed with the continuous monitoring of mean arterial blood pressure, as wellas of the cerebral blood flow velocities, in the middle cerebral artery, bilaterally, during passivemovements of Trendelenbourg and Reverse Trendelenbourg, at 45ο, sequentially. The cerebralability of altering its perfusion and metabolism status was checked, again bilaterally, with themeasurement of the parametres mentioned above, after 1 min of active and passive movement ofthe right and left elbow and hand, with one movement happening after the other. All themeasurements mentioned above, were also evaluated in the subgroups of cirrhotic patients, with orwithout hepatic encephalopathy, with or without portal hypertension and according to the Child –Pugh stage of the disease. In all the subjects that were tested basic cardiorespiratory parametreswere recorded, at predetermined checking time – points. Finally, blood samples were withdrawnfrom both patients and healthy volunteers for investigation of basic haematological and biochemicalparametres, analysis of arterial blood gases and determination of the S100b protein blood levels.ResultsDuring the cross – sectional phase of our study, the cerebral blood flow velocities were found to belower in patients with chronic liver disease, when compared to healthy volunteers, without anysignificant differences between patients with or without cirrhosis. In addition, regarding TCDvelocities, important deviations were noticed in between cirrhotic patients of various stages, withthe detection of the lowest values in those of Child – Pugh Stage C. Furthermore, we foundstatistically significant differences, bilaterally, in between cirrhotic patients with or without hepaticencephalopathy, but without any strong correlation to its stage. PI and RI were significantly higher inpatients with cirrhosis than in controls and non – cirrhotic patients with chronic hepatic disease.Hepatic Encephalopathy patients were characterized by higher cerebral vascular resistance, compared to cirrhotic patients without any cerebral derangement. Similar results wereextrapolated from the Cerebral Oximetry measurements, with the lowest values of rSO2 beingdetected in patients of Child – Pugh Stage C and in those with hepatic encephalopathy also of Stage3. PI and RI were significantly correlated with the severity of cirrhosis and the existence of hepaticencephalopathy. In addition, they were significantly correlated with blood ammonia levels, PT andserum levels of albumin and bilirubin. Both Vmean and rSO2, as well as PI and RI were stronglycorrelated with S100b blood levels. In subjects with the highest values of S100b, the lowest values ofVmean and rSO2 were measured, whereas the highest PI and RI were calculated.During the longitudinal phase of our study, which refers to the autoregulatory mechanism testing,the following were noticed. Head down or head up provoked an increase or drop in blood pressurerespectively in all the subjects that were examined. Healthy controls and non cirrhotic patients had aprompt recovery of Vmean and a progressive recovery of arterial pressure, so that, after 120 sec,both parametres had returned to baseline. At 20 sec the recovery of flow velocity was faster thanthat of blood pressure. By contrast, patients with cirrhosis had a delayed and incomplete recovery ofboth parametres. The recovery of mean velocity paralleled that of arterial pressure, indicating animpaired cerebral autoregulation. Regarding passive and active movements of elbows and hands,we noticed an ipsilateral and contralateral increase of blood flow velocities and cerebral Oximetryvalues, but without any statistically significant differences between control subjects and chronichepatic patients, or their subgroups.ConclusionsThe results of this cross sectional and longitudinal study indicate that cerebral blood flow velocitiesand cerebral oximetry values are decreased in patients with chronic liver disease, whereas PI and RIare elevated, in strong correlation with the liver failure stage, the cirrhosis stage and the presence ofhepatic encephalopathy. This conclusion becomes more powerful when we take into account thestrong correlation of the measured indices and the levels of S100b protein. Cerebral autoregulationmechanism is often impaired in chronic hepatic patients, especially those with decompensatedcirrhosis. These patients can easily develop cerebral hypoperfusion, if arterial pressure falls abruptly.TCD Ultrasonography and Near Infrared Spectroscopy (Cerebral Oximetry) provide real time anduseful indices to assess and monitor cirrhotic patients and subjects with chronic liver failure.


Sign in / Sign up

Export Citation Format

Share Document